Interesting how avi followed your post within seconds. You guys are great. But you;re exposed. You won't fool anybody on this board, for sure..................I'll keep an eye on you sabaid. The basher that you are...............Too funny.............................
Sabaid, are you a bashing on the sly. You already stated that you sold out your position in RXI, yet you remain to bash the company..............How telling, Get lost jerk... not to be trusted,
hanna, a therapeutic for an unmet need. There are no other FDA approved drugs shown to reduce the growth of scars an keloids. There are no remedies to which rx-109 need to prove as a superior.
Even a modest improvement in growth reduction will result in positive outcome. Not forget. these trials allow for the fine tuning of dosage an time.................GLTA
Then, lets hope that he has a plan for one more feather on his cap, Both for himself and his staff which he holds in such high esteem. Last but not least, for his shareholders, of which on many occasion he mentioned, he also holds in high esteem GLTA
at Johnson & Johnson, where he was employed for 23 years. He served at Johnson & Johnson (in both the U.S. and Europe) Consumer and Personal Care Products Companies from 2000 to 2002, where Dr. Cauwenbergh served as Vice President of Technology, where he created technology platforms based on intellectual property and know-how owned by it and developed a business proposition around these platforms as the basis for new companies or new businesses within or outside it. From 1994 to 2000, Dr. Cauwenbergh served as Global Vice President of Research & Development at Johnson & Johnson Consumer Companies Worldwide. He served as Vice President, Research and Development for Johnson & Johnson's Skin Research Center, and was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. Dr. Cauwenbergh served as Vice President, Product Development and a Member of the Management Board of U.S. J&J Consumer Company since 1994. He served as the Director of Corporate Skin Care Council of J&J, co-ordinating all skin care activities in the different operating groups of Corporation. In his career, he served positions in sales, and national and international marketing, and he was responsible for the successful global introduction of Nizoral (ketoconazole). His R&D activities had also involved him in the fields of psoriasis, acne, wound healing, atopic dermatitis, protozoal infections, and HIV.
Just a reminder that he knows his business inside and out. Criticism may be due per a couple bungled presentations resulting in part at least of the disappointing stock performance no doubt. In spite of such, I remain long, thinking there is more to RXI's "well conceived plan" in store....GLTA
Glad you're around avi, it's a good sign to have a hedge fund messenger boy bashing full time. Only one thing, you really stink. Everybody can actually smell you from where they live. Not nice at all............Whewww......... BTW he's not a podiatrist. He's a dermatologist......GL to everybody but you avi..............
Not to say I,m less than optimistic of the trials. Scarring and keloids is an unmet need. Many therapies are available, but none as yet that can prevent their growth. RXI may well be first with this therapy. P2 very close. I remain long............GL
Do they possess the depth in their science and IP to overcome the possible failure of scar trials. P2 trials go beyond scarring, as its success opens the opthalmology "franchise" as Geert calls it. It's questionable if opthal will advance to the clinic without confirmation of success of 109 which will confirm sdrx. Not to say that rx-109 may actually stand a better chance in opthamology, but that the timeframe will be too difficult to overcome Unless I'm reading it wrong, the p2 trials are crucial.................just a thought this afternoon.....GLTA
Perhaps what you meant was that you wish "Bitterman bought 50k shs instead of 5k shs. He in fact bought 5k shs, whatever that means................GLTA
gb42bthyfiy, some reply to the bashers for good reason. Yet, you reply to the morons? You sound like a real idiot. .....................GLTA
But I can still smell the stench of the miscreant avimorax. Can you smell him from where you live/........
ooooo he stinks....................
Upon approval, could be in P1 sooner than I thought.
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. The FDA reviews the IND application for safety to assure that research subjects will not be subjected to unreasonable risk. If the application is cleared, the candidate drug usually enters a Phase 1.
They're not sitting on their hands art RXI, I'll say that much. While the stock's performance is dismal , I doubt is has any effect on company business..........GLTA
Until more data is released on the trials we remain stagnant or even lower. I don't see the rush for any big players or pharma to make substantial commitments until further confirmation. Wouldn't it be prudent for them to wait......................GLTA
Can you explain how these company's stock decline are the direct result of LPC financing or could they have been the result of the norm of the volatility of microcap biotech it which multiple factors possible cause?........thanks
Very similar to credit line, with the difference being with little or nothing to collateralize, therefore, their fee comes off the top as grab points out. LPC's funding expensive. Hoping that it may be limited to a minimum and possibly (just possibly) not needed in the near future...............GLTA